# Brain Metastases: Surgical Decision-Making

## Overview

Brain metastases are the most common intracranial tumors in adults, outnumbering primary brain tumors by approximately 10:1. They occur in 20-40% of cancer patients. The most common primary sources are lung (40-50%), breast (15-20%), melanoma (5-10%), renal cell carcinoma (5-10%), and colorectal cancer (3-5%). Management requires a multidisciplinary approach integrating surgery, stereotactic radiosurgery (SRS), whole-brain radiation therapy (WBRT), and systemic therapy.

## Pathophysiology

Brain metastases reach the brain via hematogenous spread through the arterial circulation. Most develop at the gray-white matter junction, where narrowing arterioles trap tumor emboli. Their distribution follows cerebral blood flow patterns: approximately 80% occur in the cerebral hemispheres, 15% in the cerebellum, and 5% in the brainstem. Metastases typically grow as well-circumscribed lesions surrounded by a gliotic pseudocapsule that separates them from the surrounding brain. Vasogenic edema is prominent due to breakdown of the blood-brain barrier.

## Diagnosis and Imaging

### MRI Features

On T1-weighted imaging with gadolinium, metastases appear as uniformly or ring-enhancing, well-circumscribed lesions at the gray-white junction. T2/FLAIR sequences show surrounding vasogenic edema, often disproportionate to tumor size. Diffusion characteristics vary depending on cellularity. Susceptibility-weighted imaging (SWI/GRE) reveals hemorrhagic metastases, which are characteristic of melanoma, renal cell carcinoma, choriocarcinoma, and thyroid carcinoma. Thin-slice (1 mm) gadolinium-enhanced MRI is essential for accurate lesion count. Leptomeningeal disease manifests as enhancement along the sulci and cranial nerves on post-contrast imaging.

### Differential Diagnosis

Brain abscess is distinguished by central restricted diffusion. High-grade glioma shows irregular enhancement with infiltrative margins and crosses white matter tracts. Lymphoma typically enhances homogeneously in a periventricular location with diffusion restriction throughout. Demyelinating disease displays incomplete ring enhancement.

### Prognostic Scoring Systems

The Recursive Partitioning Analysis (RPA) classifies patients into Classes I-III based on age, KPS, primary tumor control, and extracranial disease. The Graded Prognostic Assessment (GPA) offers more refined stratification by including the number of metastases. The Diagnosis-Specific GPA (ds-GPA) incorporates molecular markers for specific tumor types, such as HER2 status in breast cancer, BRAF/EGFR status in lung cancer, and BRAF status in melanoma.

| Scoring System | Variables | Classes | Median Survival Range |
|---------------|-----------|---------|----------------------|
| RPA | Age, KPS, primary control, extracranial disease | I, II, III | 2-7 months |
| GPA | Age, KPS, number of mets, extracranial disease | 0-4 (0.5 increments) | 3-14 months |
| ds-GPA | Tumor-specific variables + molecular markers | Varies by histology | Histology-dependent |

<image>
Axial T1-weighted post-gadolinium MRI showing three ring-enhancing metastases at the gray-white matter junction in different lobes (frontal, parietal, and occipital) with surrounding vasogenic edema visible on the adjacent FLAIR image. One lesion shows hemorrhagic components on the SWI sequence. Radiological teaching illustration with labeled sequences and key features annotated.
</image>

## Surgical Management

### Indications for Surgery

Surgery is indicated for single or limited metastases in surgically accessible locations, when tissue diagnosis is needed (unknown primary or uncertain diagnosis), for large lesions with significant mass effect requiring urgent decompression, for symptomatic lesions not responsive to steroids, for posterior fossa lesions with hydrocephalus or brainstem compression, for radioresistant histologies (melanoma, renal cell carcinoma, sarcoma), and when the patient has good performance status (KPS of 70 or greater) and reasonable life expectancy exceeding 3 months.

### Contraindications to Surgery

Surgery is generally not indicated when multiple metastases (more than 3-4) are amenable to SRS, for deep-seated or brainstem lesions, in the setting of widely disseminated systemic disease with poor prognosis, with poor performance status (KPS below 70), in leptomeningeal carcinomatosis, or for highly chemo- or radiosensitive tumors such as small cell lung cancer, lymphoma, or germ cell tumors.

### Landmark Surgical Trials

Patchell et al. (1990) demonstrated that surgery plus WBRT significantly improved overall survival (40 versus 15 weeks), local control, and functional independence compared with WBRT alone for single brain metastases. Vecht et al. (1993) confirmed this survival benefit. However, Mintz et al. (1996) showed no benefit of surgery in patients with poor prognostic factors including low KPS and active systemic disease, highlighting the critical importance of patient selection.

### Surgical Technique

En bloc resection is preferred over piecemeal removal to reduce local recurrence and leptomeningeal seeding. The surgeon performs circumferential dissection along the gliotic pseudocapsule plane while avoiding entry into the tumor capsule to minimize tumor cell spillage. Supramarginal resection, which removes a rim of surrounding brain with the tumor, may reduce local recurrence but must be balanced against functional risk. Fluorescein sodium or 5-ALA may improve visualization of tumor margins in selected cases. Intraoperative ultrasound or neuronavigation assists with tumor localization. Posterior fossa metastases represent an urgent surgical indication if causing obstructive hydrocephalus or brainstem compression, and an EVD may be needed preoperatively.

## Postoperative Cavity Management

### Postoperative SRS vs. WBRT

Patchell et al. (2002) showed that adding WBRT after surgery reduced local and distant brain recurrence but did not improve overall survival, while causing neurocognitive decline. Brown et al. (2017, N0574) demonstrated that postoperative SRS to the resection cavity resulted in less cognitive decline with similar overall survival compared to WBRT; local control was slightly lower with SRS but distant brain failure rates were similar. Mahajan et al. (2017) showed that postoperative SRS to the cavity reduced local recurrence from 43% to 28% at 12 months compared with observation alone. The current standard is postoperative SRS to the resection cavity rather than WBRT, to preserve neurocognition.

### Timing of Postoperative SRS

Postoperative SRS is typically delivered within 3-4 weeks of surgery to allow wound healing. Preoperative SRS is an emerging concept that may improve local control and reduce leptomeningeal dissemination.

## Stereotactic Radiosurgery (Without Surgery)

### Indications

SRS without surgery is appropriate for 1-4 metastases (some centers treat up to 10-15 with modern protocols), lesions 3-4 cm or smaller in maximum diameter, surgically inaccessible lesions, when patient preference or medical comorbidities preclude surgery, and for radiosensitive histologies.

### Dosing

Typical single-fraction doses are 18-24 Gy for lesions under 2 cm, 15-18 Gy for 2-3 cm lesions, and 12-15 Gy for 3-4 cm lesions. RTOG 90-05 established maximum tolerated doses based on tumor size. Fractionated SRS in 3-5 fractions is used for larger lesions or those adjacent to critical structures.

| Tumor Size | Single-Fraction SRS Dose | Notes |
|-----------|-------------------------|-------|
| <2 cm | 18-24 Gy | Highest local control rates |
| 2-3 cm | 15-18 Gy | Intermediate dose |
| 3-4 cm | 12-15 Gy | Consider fractionated SRS |
| >4 cm | Fractionated (3-5 fractions) | Not ideal for single-fraction SRS |

### Whole-Brain Radiation Therapy

WBRT is increasingly reserved for diffuse metastatic disease, leptomeningeal disease, or poor surgical/SRS candidates. The QUARTZ trial showed no overall survival difference between WBRT and best supportive care in NSCLC patients with brain metastases not suitable for surgery or SRS, questioning the utility of WBRT in poor-prognosis patients. NRG CC001 demonstrated that hippocampal-avoidance WBRT plus memantine reduced cognitive decline compared with standard WBRT. Typical WBRT doses are 30 Gy in 10 fractions or 20 Gy in 5 fractions.

<image>
Stereotactic radiosurgery treatment plan showing a single brain metastasis in the right parietal lobe with dose-volume histogram and isodose lines. The prescription isodose line (e.g., 20 Gy) conformally covers the tumor with rapid dose falloff to surrounding brain tissue. An adjacent panel shows the corresponding MRI with the lesion. Clean medical illustration demonstrating SRS planning principles.
</image>

## Role of Systemic Therapy

Targeted therapies that cross the blood-brain barrier are increasingly important. EGFR inhibitors such as osimertinib achieve intracranial response rates exceeding 80% for EGFR-mutant NSCLC brain metastases. ALK inhibitors including lorlatinib and alectinib are effective for ALK-rearranged NSCLC. HER2-targeted agents like tucatinib plus trastuzumab benefit HER2-positive breast cancer. In the immunotherapy space, combination ipilimumab plus nivolumab achieves intracranial response rates of 46-55% for melanoma brain metastases, and checkpoint inhibitors are showing activity in NSCLC brain metastases. In selected patients with responsive disease, systemic therapy may allow deferral of local therapy.

## Special Considerations

### Hemorrhagic Metastases

Melanoma, renal cell carcinoma, choriocarcinoma, and thyroid carcinoma are prone to hemorrhagic metastases. Acute hemorrhage may require emergent surgical evacuation, and intraoperative hemostasis can be challenging.

### Posterior Fossa Metastases

These carry the risk of obstructive hydrocephalus and rapid brainstem compression, warranting a lower threshold for surgical intervention. Preoperative EVD may be necessary. CSF diversion alone is insufficient; definitive treatment of the mass is required.

### Radiation Necrosis vs. Recurrence

Both present as enhancing lesions on follow-up MRI. MR perfusion with low rCBV favors necrosis while high rCBV favors recurrence. PET with amino acid tracers is helpful for differentiation. MR spectroscopy showing an elevated choline-to-creatinine ratio suggests recurrence. Biopsy or resection may be required for definitive diagnosis.

<image>
Decision algorithm for the management of brain metastases starting with the number of lesions (single, 2-4, or multiple >4), branching through assessment of surgical accessibility, lesion size, performance status, and systemic disease status. Treatment pathways lead to surgery + cavity SRS, SRS alone, WBRT, or systemic therapy. Molecular markers and histology-specific considerations are noted at relevant decision points. Clean flowchart with color-coded pathways.
</image>

## Clinical Pearls

En bloc resection along the gliotic pseudocapsule reduces local recurrence and leptomeningeal seeding compared with piecemeal debulking. Postoperative cavity SRS is now preferred over WBRT to preserve neurocognitive function, reflecting a paradigm shift based on N0574 and related trials. One should always check for an unknown primary before assuming a brain lesion is a metastasis, since solitary ring-enhancing lesions in patients without known cancer may represent GBM, abscess, or other pathology. Posterior fossa metastases demand urgent attention because cerebellar herniation can occur rapidly and decompression should not be delayed. Melanoma and RCC metastases are relatively radioresistant to conventional fractionated RT but respond well to SRS and surgery. Systemic therapy advances such as osimertinib and checkpoint immunotherapy are increasingly providing intracranial disease control, sometimes allowing deferral of local therapies. Dexamethasone effectively controls peritumoral edema but should be tapered rapidly, with particular caution when concurrent immunotherapy is being administered, as steroids may blunt the immune response.

## References
- Patchell RA, et al. "A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain." *NEJM*. 1990;322(8):494-500.
- Patchell RA, et al. "Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain." *JAMA*. 1998;280(17):1485-1489.
- Brown PD, et al. "Postoperative Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy for Resected Metastatic Brain Disease (N0574)." *Lancet Oncol*. 2017;18(8):1049-1060.
- Mahajan A, et al. "Post-operative Stereotactic Radiosurgery versus Observation for Completely Resected Brain Metastases." *Lancet Oncol*. 2017;18(8):1040-1048.
- Sperduto PW, et al. "Diagnosis-Specific Graded Prognostic Assessment (ds-GPA)." *JCO*. 2012;30(4):419-425.